103 related articles for article (PubMed ID: 21040762)
41. New insights into generalized hepatoprotective effects of oleanolic acid: key roles of metallothionein and Nrf2 induction.
Liu J; Wu Q; Lu YF; Pi J
Biochem Pharmacol; 2008 Oct; 76(7):922-8. PubMed ID: 18706400
[TBL] [Abstract][Full Text] [Related]
42. Diminished molecular response to doxorubicin and loss of cardioprotective effect of dexrazoxane in Egr-1 deficient female mice.
Saadane N; Yue P; Alpert L; Mitmaker B; Kirby GM; Chalifour LE
Can J Physiol Pharmacol; 2001 Jun; 79(6):533-44. PubMed ID: 11430591
[TBL] [Abstract][Full Text] [Related]
43. Mercury accumulation and its distribution to metallothionein in mouse brain after sub-chronic pulse exposure to mercury vapor.
Yasutake A; Sawada M; Shimada A; Satoh M; Tohyama C
Arch Toxicol; 2004 Sep; 78(9):489-95. PubMed ID: 15138662
[TBL] [Abstract][Full Text] [Related]
44. Cardiotoxicity of doxorubicin/paclitaxel combination in rats: effect of sequence and timing of administration.
Saad SY; Najjar TA; Alashari M
J Biochem Mol Toxicol; 2004; 18(2):78-86. PubMed ID: 15122649
[TBL] [Abstract][Full Text] [Related]
45. Zinc-induced metallothionein overexpression prevents doxorubicin toxicity in cardiomyocytes by regulating the peroxiredoxins.
Jing L; Li L; Zhao J; Zhao J; Sun Z; Peng S
Xenobiotica; 2016 Aug; 46(8):715-25. PubMed ID: 26599915
[TBL] [Abstract][Full Text] [Related]
46. Effect of alprazolam on anxiety and cardiomyopathy induced by doxorubicin in mice.
Anwar MJ; Pillai KK; Khanam R; Akhtar M; Vohora D
Fundam Clin Pharmacol; 2012 Jun; 26(3):356-62. PubMed ID: 21352350
[TBL] [Abstract][Full Text] [Related]
47. Novel roles for metallothionein-I + II (MT-I + II) in defense responses, neurogenesis, and tissue restoration after traumatic brain injury: insights from global gene expression profiling in wild-type and MT-I + II knockout mice.
Penkowa M; Cáceres M; Borup R; Nielsen FC; Poulsen CB; Quintana A; Molinero A; Carrasco J; Florit S; Giralt M; Hidalgo J
J Neurosci Res; 2006 Nov; 84(7):1452-74. PubMed ID: 16941634
[TBL] [Abstract][Full Text] [Related]
48. VEGF-B gene therapy inhibits doxorubicin-induced cardiotoxicity by endothelial protection.
Räsänen M; Degerman J; Nissinen TA; Miinalainen I; Kerkelä R; Siltanen A; Backman JT; Mervaala E; Hulmi JJ; Kivelä R; Alitalo K
Proc Natl Acad Sci U S A; 2016 Nov; 113(46):13144-13149. PubMed ID: 27799559
[TBL] [Abstract][Full Text] [Related]
49. Liposomal doxorubicin attenuates cardiotoxicity via induction of interferon-related DNA damage resistance.
Gyöngyösi M; Lukovic D; Zlabinger K; Spannbauer A; Gugerell A; Pavo N; Traxler D; Pils D; Maurer G; Jakab A; Riesenhuber M; Pircher A; Winkler J; Bergler-Klein J
Cardiovasc Res; 2020 Apr; 116(5):970-982. PubMed ID: 31346605
[TBL] [Abstract][Full Text] [Related]
50. Folic acid reduces doxorubicin-induced cardiomyopathy by modulating endothelial nitric oxide synthase.
Octavia Y; Kararigas G; de Boer M; Chrifi I; Kietadisorn R; Swinnen M; Duimel H; Verheyen FK; Brandt MM; Fliegner D; Cheng C; Janssens S; Duncker DJ; Moens AL
J Cell Mol Med; 2017 Dec; 21(12):3277-3287. PubMed ID: 28608983
[TBL] [Abstract][Full Text] [Related]
51. Microarray and Co-expression Network Analysis of Genes Associated with Acute Doxorubicin Cardiomyopathy in Mice.
Wei SN; Zhao WJ; Zeng XJ; Kang YM; Du J; Li HH
Cardiovasc Toxicol; 2015 Oct; 15(4):377-93. PubMed ID: 25575753
[TBL] [Abstract][Full Text] [Related]
52. Doxorubicin and NRG-1/erbB4-Deficiency Affect Gene Expression Profile: Involving Protein Homeostasis in Mouse.
Vasti C; Witt H; Said M; Sorroche P; García-Rivello H; Ruiz-Noppinger P; Hertig CM
ISRN Cardiol; 2012; 2012():745185. PubMed ID: 22970387
[TBL] [Abstract][Full Text] [Related]
53. Anthracycline antibiotics as cellular disruptors: insights into anthracycline-induced cardiomyopathy.
Lewis W; Amelar SE; Puszkin S
Mt Sinai J Med; 1984 Jun; 51(3):246-53. PubMed ID: 6205261
[No Abstract] [Full Text] [Related]
54. Focal adhesion kinase antagonizes doxorubicin cardiotoxicity via p21(Cip1.).
Cheng Z; DiMichele LA; Rojas M; Vaziri C; Mack CP; Taylor JM
J Mol Cell Cardiol; 2014 Feb; 67():1-11. PubMed ID: 24342076
[TBL] [Abstract][Full Text] [Related]
55. Upregulation of Biomarker Limd1 Was Correlated with Immune Infiltration in Doxorubicin-Related Cardiotoxicity.
Zhang R; Hao C; Ji Z; Qu Y; Zuo W; Yang M; Zuo P; Carvalho A; Ma G; Li Y
Mediators Inflamm; 2023; 2023():8347759. PubMed ID: 37009626
[TBL] [Abstract][Full Text] [Related]
56. SKI activates the Hippo pathway via LIMD1 to inhibit cardiac fibroblast activation.
Landry NM; Rattan SG; Filomeno KL; Meier TW; Meier SC; Foran SJ; Meier CF; Koleini N; Fandrich RR; Kardami E; Duhamel TA; Dixon IMC
Basic Res Cardiol; 2021 Apr; 116(1):25. PubMed ID: 33847835
[TBL] [Abstract][Full Text] [Related]
57. Effects of Doxorubicin on Heme Biosynthesis and Metabolism in Cardiomyocyte.
Wang Z; Gao J; Teng H; Peng J
Arq Bras Cardiol; 2021 Feb; 116(2):315-322. PubMed ID: 33656082
[TBL] [Abstract][Full Text] [Related]
58. miR-550a-5p Functions as a Tumor Promoter by Targeting LIMD1 in Lung Adenocarcinoma.
Guo ZZ; Ma ZJ; He YZ; Jiang W; Xia Y; Pan CF; Wei K; Shi YJ; Chen L; Chen YJ
Front Oncol; 2020; 10():570733. PubMed ID: 33194664
[TBL] [Abstract][Full Text] [Related]
59. Noncoding RNAs in doxorubicin-induced cardiotoxicity and their potential as biomarkers and therapeutic targets.
Fa HG; Chang WG; Zhang XJ; Xiao DD; Wang JX
Acta Pharmacol Sin; 2021 Apr; 42(4):499-507. PubMed ID: 32694762
[TBL] [Abstract][Full Text] [Related]
60. The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity.
Timm KN; Tyler DJ
Cardiovasc Drugs Ther; 2020 Apr; 34(2):255-269. PubMed ID: 32034646
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
